Zacks Research Issues Optimistic Forecast for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Equities researchers at Zacks Research lifted their Q2 2026 earnings per share (EPS) estimates for Corcept Therapeutics in a note issued to investors on Thursday, May 21st. Zacks Research analyst Team now forecasts that the biotechnology company will earn ($0.05) per share for the quarter, up from their prior estimate of ($0.06). Zacks Research has a “Hold” rating on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $0.52 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.47 EPS, FY2026 earnings at $0.38 EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at $0.26 EPS, Q3 2027 earnings at $0.57 EPS, Q4 2027 earnings at $0.59 EPS, FY2027 earnings at $1.25 EPS and Q1 2028 earnings at $0.20 EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Thursday, April 30th. The biotechnology company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.19). Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. The business had revenue of $164.90 million during the quarter, compared to analyst estimates of $185.83 million. During the same quarter in the prior year, the company posted $0.17 earnings per share. The company’s revenue was up 4.9% on a year-over-year basis.

Other equities research analysts have also recently issued reports about the company. Truist Financial raised Corcept Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Wolfe Research upgraded Corcept Therapeutics from an “underperform” rating to a “peer perform” rating in a report on Thursday, March 26th. Piper Sandler boosted their price objective on Corcept Therapeutics from $73.00 to $88.00 and gave the company an “overweight” rating in a report on Friday, May 1st. Canaccord Genuity Group boosted their price objective on Corcept Therapeutics from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Finally, HC Wainwright boosted their price objective on Corcept Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $70.83.

Corcept Therapeutics Price Performance

Shares of NASDAQ CORT opened at $60.22 on Monday. The firm has a market cap of $6.46 billion, a price-to-earnings ratio of 172.06 and a beta of 0.36. Corcept Therapeutics has a 52-week low of $28.66 and a 52-week high of $91.00. The business’s 50 day moving average is $44.79 and its two-hundred day moving average is $52.46.

Institutional Trading of Corcept Therapeutics

Large investors have recently modified their holdings of the stock. Advisory Services Network LLC purchased a new stake in shares of Corcept Therapeutics during the third quarter worth $25,000. Clearstead Advisors LLC increased its position in shares of Corcept Therapeutics by 163.6% during the third quarter. Clearstead Advisors LLC now owns 311 shares of the biotechnology company’s stock worth $26,000 after acquiring an additional 193 shares during the period. Hantz Financial Services Inc. increased its position in shares of Corcept Therapeutics by 598.5% during the third quarter. Hantz Financial Services Inc. now owns 461 shares of the biotechnology company’s stock worth $38,000 after acquiring an additional 395 shares during the period. Larson Financial Group LLC increased its holdings in Corcept Therapeutics by 2,326.3% in the third quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 442 shares during the last quarter. Finally, Gould Capital LLC increased its holdings in Corcept Therapeutics by 50.0% in the third quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Insider Transactions at Corcept Therapeutics

In other news, insider William Guyer sold 20,000 shares of the company’s stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $51.83, for a total transaction of $1,036,600.00. Following the sale, the insider owned 2,231 shares of the company’s stock, valued at approximately $115,632.73. This represents a 89.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director G Leonard Baker, Jr. acquired 100,000 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were bought at an average cost of $33.14 per share, for a total transaction of $3,314,000.00. Following the transaction, the director directly owned 1,146,631 shares of the company’s stock, valued at approximately $37,999,351.34. This trade represents a 9.55% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders have sold 86,198 shares of company stock valued at $3,887,769. 20.70% of the stock is currently owned by company insiders.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks Research raised multiple earnings estimates for Corcept Therapeutics, including Q2 2026, Q3 2026, Q4 2026, FY2026, Q1 2027, Q2 2027, Q3 2027, and Q1 2028, suggesting a better earnings outlook ahead.
• Positive Sentiment: The biggest near-term boost was in FY2026, where Zacks lifted its EPS forecast to $0.38 from $0.20, which may reassure investors that profitability is improving faster than previously expected.
• Positive Sentiment: Analysts also increased estimates for Q2 2027 and Q3 2027, indicating confidence that Corcept’s earnings growth can continue beyond the next few quarters.
• Neutral Sentiment: Zacks Research kept a Hold rating on the stock, so the research update was constructive on earnings but not a full bullish call.
• Negative Sentiment: The firm lowered its FY2027 EPS estimate to $1.25 from $1.67 and cut Q3 2027 and Q4 2027 forecasts, showing some caution about longer-term earnings momentum.

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.